GSK3B and cholangiocarcinoma: To determine whether CAFs could also activate GSK3β and P65 in CCA cells through PDGF-BB/PDGFR-β, we added PDGF-BB neutralizing antibodies to the supernatant or pretreated CCA cells with a PDGFR-β inhibitor.